Market News & Trends
Fate Therapeutics Presents its First Off-the-Shelf, iPSC-Derived CAR T-Cell Immunotherapy Program
Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the…
Retrogenix & Resonant Therapeutics Announce Strategic Alliance
Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the…
Navigen Announces FDA Clearance of its IND Application
Navigen, Inc. recently announced the US FDA has cleared its Investigational New Drug application (IND) for the initiation of a Phase 1 study in healthy…
Bioncotech Therapeutics Announces Oncology Clinical Trial Collaboration With MSD
Bioncotech Therapeutics recently announced it has entered into a Phase 2 clinical trial collaboration with a subsidiary of Merck & Co., Inc., Kenilworth, NJ, known…
Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial
Dermavant Sciences recently announced that the first patient has been dosed in its Phase 2a vitiligo clinical trial for topical cerdulatinib. Cerdulatinib is a dual…
CicloMed Expands Fosciclopirox Phase 1 Trial
CicloMed LLC recently announced the expansion of its fosciclopirox clinical development program. The fosciclopirox first-in-human Phase 1 trial has been expanded to include patients with…
Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial
Soligenix, Inc. recently announced it has completed patient enrollment in its Phase 3 "Fluorescent Light Activated Synthetic Hypericin" (FLASH) study for SGX301 (synthetic hypericin) in…
Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial
Cara Therapeutics, Inc. recently announced positive topline results from its Phase 2 dose-ranging trial of Oral KORSUVAT (CR845/difelikefalin) for the treatment of pruritus in patients…
Vivera Pharmaceuticals Enters Agreement Clinical Study Agreement With Parexel Biotech
Vivera Pharmaceuticals, Inc. recently announced it has signed an agreement for Clinical Development Services with Parexel International, a leading provider of solutions to accelerate the…
IONTAS & Adaptate Biotherapeutics Enter Collaboration Agreement
IONTAS Limited recently announced it has entered into a collaboration agreement with Adaptate Biotherapeutics to generate and optimize antibodies for novel immuno-oncology targets, including access…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….